Results from Phase II studies demonstrated that rilzabrutinib showed clinically meaningful outcomes in patients with warm ...

Sanofi has returned to Nurix Therapeutics for another autoimmune candidate, paying $15 million and committing up to $465 ...

"I think we were contrarians,” Sanofi's chief digital officer Emmanuel Frenehard told Fortune. “I think the contrarians are ...

Sanofi’s treatment for hemophilia that can be administered as infrequently as once every other month, was approved by the US ...

Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more ...

Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless ...

On the occasion of French President Emmanuel Macron’s official visit to Egypt, Sanofi, a global healthcare leader in the ...

French pharma major Sanofi and investment firm Cathay Capital have launched a $275 million fund that will invest in ...

Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on Sanofi (SNYNF – Research Report), with a price ...

Sanofi's Qfitlia gains FDA approval, offering fewer injections in hemophilia care. Check out my recommendation for SNY stock.

Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Results from the HERCULES phase 3 study showed delay in disability progression in people ...